Drive payer submission readiness for Phase 2 and 3 product

Engaging the full workforce—from HR to R&D—can elevate launch outcomes, build trust, and create long-term brand ambassadors.

Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

The US president says the levies on pharmaceutical imports are imminent, but won’t take effect for a year to a year and a half.

Tracy Lopez uncovers the fundamentals pertaining to third-party logistics providers.

Amid the push for reshoring and fiscal reform, the tariffs are part of a broader effort to rebalance trade and fund domestic initiatives, as the pharma sector awaits potential levies of its own.

The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient needs through domestic innovation and capacity.